OUR VISION

 

The field of cancer is in great need of improved diagnostics to increase the survival rate.

NeoProteomics AB has its focus on cancer diagnostic technologies. Our vision is to supply specific and safe diagnostics for more accurate and early detection of aggressive cancers. Analysis of an ordinary blood sample will eliminate the need for painful, difficult and burdening biopsies.

The company was started to enable technology and product development based on the ground breaking research in cancer proteomics from Professor Gert Auers laboratory at Karolinska Institutet.

BACKGROUND

 

Professor Gert Auer at Karolinska Institutet and his group have investigated the proteome signature of different cancers for more than a decade. This work has resulted in identifying a great number of potential biomarkers. Apart from Professor Auers research at Karolinska Institutet, he is also an active cell and molecular pathologist thereby having an everyday experience of today’s challenges in cancer diagnostics.

NeoProteomics AB started the development of biomarkers for sensitive and risk-free cancer diagnosis by analyzing platelets role  in cancer.

Today, the company consists of a core development team based at the Karolinska Institutet. Head of the company is Torbjörn Pettersson who contributes with decades of commercial and scientific experience.

COLLABORATIONS

 

NeoProteomics collaborates with a research group at the University Hospital in Lübeck, Germany, led by Professor Jens Habermann.

Validation of the technology and upcoming products are performed within the Vinnova funded project “Innovations for Future Health” in collaboration with Karolinska University Hosptital in Stockholm and Akademiska Hospital in Uppsala, Sweden.

The assay validation and development is performed in close collaboration with The Natural and Medicinal Sciences Institute (NMI) at the University of Tübingen, Germany.

INVESTORS

 

NeoProteomics is financed by several private investors headed by the main owner and lead investor Johan Enocson, Active Invest Sweden AB.
The company has also got major project contributions from Vinnova.